EX-16.1 2 f8k041019bex16-1_immucell.htm LETTER FROM RSM US LLP TO THE SECURITIES AND EXCHANGE COMMISSION.

Exhibit 16.1

 

 

April 12, 2019

 

 

Securities and Exchange Commission

Washington, D.C. 20549

 

Commissioners:

 

We have read ImmuCell Corporation’s statements included under Item 4.01 of its Form 8-K filed on April 12, 2019 and we agree with such statements concerning our firm.